[ Lupus découvert lors de la grossesse: A propos d’un cas avec revue de littérature ]
Volume 34, Issue 3, November 2021, Pages 497–505
H. Souradi1, Z. Bennani2, F. Amqrane3, M. Hijji4, M. Youssfi5, and Samir Bargach6
1 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
2 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
3 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
4 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
5 Department of Gynecology-obstetrics, oncology and high-risk pregnancies, Souissi Maternity Hospital, Mohamed V University, Rabat, Morocco
6 Department of Gynecology-Obstetrics-Oncology and High-Risk Pregnancy, Souissi Maternity Hospital, Ibn Sina University Hospital Center, Rabat, Morocco
Original language: French
Copyright © 2021 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Systemic lupus (LS) is an autoimmune disease mainly affecting young women of childbearing age, The occurrence of pregnancy with lupus has become a usual situation, active lupus in the 6 months preceding or at the beginning of pregnancy has more risk of having an attack, the lupus known preceding the pregnancy must make this last programmed.Maternal mortality is multiplied by 20 in lupus patients, this seems to be essentially linked to the activity of LS, the occurrence of pre-eclampsia, the presence of anti-phospholipid antibodies and the side effects of therapies, in particular infectious.Fetal and perinatal risks are linked to prematurity, the presence of maternal anti-phospholipid or anti- SSA antibodies and the side effects of treatment.The most common situation is the knowledge of lupus before pregnancy. Our case treats an unrecognized lupus triggered by pregnancy, monitoring and management must be multidisciplinary, including regular clinical, biological and ultrasound evaluation.The treatment of relapses varies according to the severity and the type of organ affected and remains similar to the treatment outside pregnancy subject to the compatibility of the treatments with this one: hydroxy chloroquine, corticosteroid bolus if necessary then orally with the lowest possible dose, which markedly improved the prognosis.
Author Keywords: Systemic lupus, young women, autoimmune disease, hydroxychloroquine, corticoides.
Volume 34, Issue 3, November 2021, Pages 497–505
H. Souradi1, Z. Bennani2, F. Amqrane3, M. Hijji4, M. Youssfi5, and Samir Bargach6
1 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
2 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
3 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
4 Service de Gynécologie-Obstétrique, de Cancérologie et de Grossesses à Haut Risque, Maternité Souissi, Université Mohamed V, Rabat, Morocco
5 Department of Gynecology-obstetrics, oncology and high-risk pregnancies, Souissi Maternity Hospital, Mohamed V University, Rabat, Morocco
6 Department of Gynecology-Obstetrics-Oncology and High-Risk Pregnancy, Souissi Maternity Hospital, Ibn Sina University Hospital Center, Rabat, Morocco
Original language: French
Copyright © 2021 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Systemic lupus (LS) is an autoimmune disease mainly affecting young women of childbearing age, The occurrence of pregnancy with lupus has become a usual situation, active lupus in the 6 months preceding or at the beginning of pregnancy has more risk of having an attack, the lupus known preceding the pregnancy must make this last programmed.Maternal mortality is multiplied by 20 in lupus patients, this seems to be essentially linked to the activity of LS, the occurrence of pre-eclampsia, the presence of anti-phospholipid antibodies and the side effects of therapies, in particular infectious.Fetal and perinatal risks are linked to prematurity, the presence of maternal anti-phospholipid or anti- SSA antibodies and the side effects of treatment.The most common situation is the knowledge of lupus before pregnancy. Our case treats an unrecognized lupus triggered by pregnancy, monitoring and management must be multidisciplinary, including regular clinical, biological and ultrasound evaluation.The treatment of relapses varies according to the severity and the type of organ affected and remains similar to the treatment outside pregnancy subject to the compatibility of the treatments with this one: hydroxy chloroquine, corticosteroid bolus if necessary then orally with the lowest possible dose, which markedly improved the prognosis.
Author Keywords: Systemic lupus, young women, autoimmune disease, hydroxychloroquine, corticoides.
Abstract: (french)
Le lupus systémique (LS) est une maladie auto-immune atteignant principalement la jeune femme en âge de procréer, La survenue d’une grossesse associée est devenue une situation habituelle, un lupus actif dans les 6 mois précédent la grossesse ou en début de celle-ci avaient plus de risque d’avoir une poussée, le lupus précédant la grossesse doit faire programmé cette dernière, La mortalité maternelle est multipliée par 20 chez les patientes lupiques, ceci paraissant essentiellement liée à l’activité du LS, à la survenue d’une pré-éclampsie, à la présence d’anticorps anti-phospholipides et aux effets secondaires des thérapeutiques, notamment infectieux.Les risques fœtaux et périnataux sont, eux, liés à la prématurité, la présence d’anticorps maternels anti-phospholipides ou anti-SSA et aux effets secondaires des thérapeutiques.La situation la plus fréquente est la connaissance du lupus avant la grossesse. Notre cas traite un lupus méconnu et déclenché par la grossesse, la surveillance et la prise en charge doit être multidisciplinaire, comportant une évaluation clinique, biologique et échographique régulière.Le traitement des poussées varie selon la sévérité et le type d’organe atteint et reste similaire au traitement en dehors de la grossesse sous réserve de la compatibilité des traitements avec celle-ci: hydroxy chloroquine, corticothérapie en bolus si nécessaire puis par voie orale avec une dose la plus basse possible, ce qui a amélioré nettement le pronostic.
Author Keywords: lupus systémique, femme jeune, maladie auto immune, hydroxychloroquine, corticoïdes.
How to Cite this Article
H. Souradi, Z. Bennani, F. Amqrane, M. Hijji, M. Youssfi, and Samir Bargach, “Lupus discovered during pregnancy: About one case with a review of the literature,” International Journal of Innovation and Applied Studies, vol. 34, no. 3, pp. 497–505, November 2021.
